Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trial designs for targeted agents.

Brigette B Y Ma1, Carolyn D Britten, Lillian L Siu

  • 1Department of Medical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada.

Hematology/Oncology Clinics of North America
|January 7, 2003
PubMed
Summary

Rational clinical trial design is crucial for developing targeted cancer therapies. Well-planned trials, supported by preclinical data and novel endpoints, ensure efficient use of resources for patient benefit.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy - a full-circle moment for nasopharyngeal cancer.

Nature reviews. Clinical oncology·2026
Same author

Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours.

British journal of cancer·2026
Same author

Hallmarks of Cancer: How did it inspire you?

Cell·2026
Same author

Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally.

Cancer discovery·2026
Same author

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.

NPJ precision oncology·2026

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Translational Medicine

Background:

  • The proliferation of targeted agents necessitates rigorous clinical trial design.
  • Understanding molecular mechanisms and preclinical data is vital for drug development.
  • Current trial designs may not suit novel targeted therapies.

Purpose of the Study:

  • To emphasize the importance of rational clinical trial design for targeted agents.
  • To advocate for the judicious use of patient resources in clinical research.
  • To promote the development and validation of innovative trial designs and endpoints.

Main Methods:

  • Review of current challenges in targeted agent development.
  • Emphasis on the integration of molecular knowledge and preclinical evidence.

Related Experiment Videos

  • Discussion of traditional versus innovative clinical trial strategies.

    • Main Results:

    • Traditional trial designs and endpoints may be insufficient for targeted drugs.
    • Premature progression from Phase I to Phase III trials should be avoided.
    • Validation of novel biologic endpoints and innovative designs is needed.

    Conclusions:

    • Well-planned clinical trials are essential for effective targeted therapy development.
    • Resources should be allocated to trials with strong scientific rationale.
    • Future research should focus on prospective validation of new trial methodologies to improve cancer patient care.